

Top five HAE projects in 2024

Product	Company	Pharma class	Route of admin	Indication	Status	Product	Indication sales (\$m)			
							2018e	2020e	2022e	2024e
Lanadelumab	Shire	Anti-plasma kallikrein MAb	Subcutaneous	Prophylactic	Filed	Lanadelumab (Shire)	70	645	1161	1569
Ruconest	Pharming	C1 esterase inhibitor	Intravenous	Episodic*	Marketed	Ruconest (Pharming)	162	292	452	614
Haegarda	CSL	C1 esterase inhibitor	Subcutaneous	Prophylactic	Marketed	Haegarda (CSL Behring)	207	311	375	319
Cinryze	Shire	C1 esterase inhibitor	Intravenous	Prophylactic	Marketed	Cinryze (Shire)	658	518	376	288
Beriner P	CSL	C1 esterase inhibitor	Intravenous	Episodic	Marketed	Beriner P (CSL Behring)	350	241	176	227

*Filed for prophylaxis. Source: EvaluatePharma.

